Elanco Animal Health에 대한 매도 수량은 투자자에게 Elanco Animal Health의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Elanco Animal Health (NYSE:ELAN) 주식, 공매도 수량 보고

Elanco Animal Health

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health Inc

ELANIX BIOTECHNOLOGIES AG by ELANIX BIOTECHNOLOGIES AG

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company's strategic direction and long-term potential through substantial share purchases.
Over the past week, CEO Dr. Jennifer Bath and BioStrand co-founders Dirk Van Hyfte and Ingrid Brands collectively acquired a total of 763,120 shares of IPA on the open market for an aggregate amount of USD $306,000.

Insider Trades

ImmunoPrecise Antibodies CEO Jennifer Bath And BioStrand Co-Founders Dirk Van Hyfte And Ingrid Brands Collectively Acquired A Total Of 763,120 Shares Of IPA On The Open Market For An Aggregate Amount Of $306,000

Loop Capital analyst Anthony Chukumba maintains Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Buy and raises the price target from $120 to $130.

Price Target

OLLI

Loop Capital Maintains Buy on Ollie's Bargain Outlet, Raises Price Target to $130

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hyliion.com&amp;esheet=54170302&amp;newsitemid=20241223192260&amp;lan=en-US&amp;anchor=Hyliion+Holdings+Corp.&amp;index=1&amp;md5=58a8e4699371f2ab58ac0b42012d441f">Hyliion Holdings Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>), a developer of sustainable electricity-producing technology, today announced it has been awarded a $6 million grant from the U.S. Department of Energy's (DOE) Methane Emissions Reduction Program. For this project, representing a total of $8.4 million in federal and non-federal funding, Hyliion will install up to 2 megawatts of KARNO&#x2122; generators in collaboration with oil and gas partners.
The project will demonstrate the KARNO generator's unique ability to operate on well-head gas to produce sustainable, near-zero emissions electricity. In 2023, Hyliion <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hyliion.com%2Fnews%2Fhyliions-karno-technology-successfully-tests-on-unprocessed-permian-basin-gas%2F&amp;esheet=54170302&amp;newsitemid=20241223192260&amp;lan=en-US&amp;anchor=successfully+tested&amp;index=2&amp;md5=e2e75dc850640b8c7be7afb60099e6d8">successfully tested</a> gas from the Permian Basin, highlighting the generator's fuel-agnostic design and its capability to utilize unprocessed gas. This distinctive capability positions the KARNO generator as a groundbreaking solution for reducing flaring and methane emissions while delivering efficient, scalable power.

Contracts

HYLN

Hyliion Awarded $6M Federal Grant To Advance Methane Emission Reductions In The Oil And Gas Industry

<ul>
<li>Brenmiller is replacing Tempo's fossil fuel boilers with a 32 MWh bGen&#x2122; thermal energy storage system to deliver sustainable process heat that is expected to mitigate 6,200 tons of carbon emissions annually</li>
<li>Tempo, partially owned by Heineken International B.V., is one of Israel's largest producers and distributors of beverages for brands including Heineken and Pepsi</li>
<li>Completion of the Tempo project as planned is expected to accelerate and support the conversion of Brenmiller's current substantial $440 million dollar commercial pipeline into projects with revenues</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbren-energy.com%2F&amp;esheet=54170268&amp;newsitemid=20241223885043&amp;lan=en-US&amp;anchor=Brenmiller+Energy+Ltd.&amp;index=1&amp;md5=a98275ef42bf19bf89bc8aef00265228">Brenmiller Energy Ltd.</a> ("Brenmiller", "Brenmiller Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>), a leading global technology provider of thermal energy storage ("TES") solutions to industrial and utility customers, today announced that it has achieved a major contractual milestone in its groundbreaking TES project for Tempo Beverages Ltd. ("Tempo") and a critical financial benchmark representing 40% of Tempo's financial commitment to the project.

BNRG

Brenmiller Energy Achieves Significant Project Milestone, On-Track To Save Tempo Beverages $7.5M In Energy Costs Using Thermal Energy Storage,  Representing 40% Of Tempo's Financial Commitment To The Project

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher premarket on Monday. On Saturday, the company successfully completed its 16th launch of the year, deploying a satellite for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42635442/rocket-lab-successfully-deploys-satellite-for-synspective-caps-off-year-with-60-increase-in-launch" rel="noreferrer noopener">Japanese Earth-observation operator</a> Synspective.
This marks the sixth of 16 planned Electron launches for Synspective. Rocket Lab has been Synspective&#8217;s exclusive launch provider since their first mission together in December 2020.
The &#8220;Owl The Way Up&#8221; mission launched from Rocket Lab&#8217;s Launch Complex 1 in Mahia, New Zealand, on December 22 at 03:17 NZT, successfully deploying a single StriX satellite into orbit via the Electron launch vehicle.
Rocket Lab founder and CEO Sir Peter Beck stated, &#8220;We look forward to continuing to increase our launch cadence in the new year as we strengthen Electron&#8217;s position as the leading small rocket globally and also enter the medium launch market with Neutron&#8217;s debut.&#8221;
Earlier this month, the company had announced &#8220;Owl The Way Up&#8221; mission, <a target="_blank" href="https://www.benzinga.com/24/12/42371072/whats-going-on-with-rocket-lab-stock-today" rel="noreferrer noopener">which is the final launch of the year</a>.
Notably, 2024 has been a remarkable year for Rocket Lab, with 16 launches so far, surpassing its previous annual record of 10 missions in 2023.
The company maintained a perfect 100% mission success rate for all 2024 launches. The company has scheduled the next Electron launch for Q1 2025.
Last week, Rocket Lab successfully delivered its second Pioneer spacecraft to Vandenberg Space Force Base and completed production <a target="_blank" href="https://www.benzinga.com/general/space/24/12/42539487/whats-going-on-with-rocket-lab-stock-tuesday-2" rel="noreferrer noopener">and testing of a third spacecraft for Varda</a>.
Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;SPDR S&amp;P Kensho Final Frontiers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKT#NYSE">ROKT</a>).
Price Action: RKLB shares are up 1.61% at $25.27 premarket at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42470053/josh-brown-unveils-the-degen-dow-a-basket-of-30-retail-darlings-spanning-all-major-degen-food-groups" target="_blank" rel="noreferrer noopener">Josh Brown Unveils The &#8216;Degen Dow,&#8217; A Basket Of 30 Retail Darlings Spanning All &#8216;Major Degen Food Groups&#8217;</a></li>
</ul>

Equities

Tech

RKLB

ROKT

Rocket Lab Ends 2024 With 16th Launch, Stock Gains

Loop Capital analyst Alan Gould maintains News (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>) with a Buy and lowers the price target from $44 to $41.

NWSA

Loop Capital Maintains Buy on News, Lowers Price Target to $41

WIIM

Xerox Holdings shares are trading higher after the company announced it agreed to acquire Lexmark International from Ninestar Corporation, PAG Asia Capital and Shanghai Shouda Investment Centre.

Macro Economic Events

Econ #s

Economics

Chicago Fed National Activity For November -0.12 Vs -0.40 Prior (Revised To -0.50)

On Monday, La Rosa Holdings Corp (NASDAQ:&nbsp;LRHC) announced it will offer Bitcoin (CRYPTO: BTC/USD) and <a target="_blank" href="https://www.benzinga.com/topic/bitcoin" rel="noreferrer noopener">other cryptocurrencies</a> as a payment option for its network of agents.
This initiative allows agents to receive certain payments in digital assets, marking a progressive step toward integrating blockchain technology into real estate transactions.
The plan addresses the growing demand for alternative payment methods among agents and clients.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42631016/taiwan-semiconductor-expands-in-japan-sony-and-denso-among-first-customers" rel="noreferrer noopener">Taiwan Semiconductor Expands in Japan: Sony and Denso Among First Customers</a>
CTO Alex Santos noted that cryptocurrency payments are a natural evolution in the company&#8217;s commitment to innovation and broker empowerment. S
antos flagged how blockchain technology offers the potential to streamline transactions while delivering unmatched flexibility in how agents and clients engage in the real estate market.
CEO Joe La Rosa expects the step to enable agents to receive their commissions in cryptocurrency. Rosa noted cryptocurrency payments offer faster, more secure transactions with lower fees while providing the potential for income growth through the value appreciation of digital assets.
Additionally, this initiative could create a new revenue stream for La Rosa, with the company implementing a 2% fee for agents who receive cryptocurrency payments.
Price Action: LRHC stock closed higher by 18.7% at $0.8072 on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42627181/blackberry-growth-hinge-on-iot-secure-communications-despite-valuation-concerns-analyst" target="_blank" rel="noreferrer noopener">BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

LRHC

EXCLUSIVE: La Rosa Adds Bitcoin and Crypto Payment Options For Network Agents

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Commercial Metals Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>)</h3>
<ul>
<li>On Dec. 12, UBS analyst Curt Woodworth downgraded Commercial Metals from Buy to Sell and lowered the price target from $62 to $56. The company's stock fell around 19% over the past month and has a <a href="https://www.benzinga.com/quote/CMC">52-week low of $47.42</a>.</li>
<li>RSI Value: 27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CMC Price Action: Shares of Commercial Metals gained 1.5% to close at $50.27 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest CMC news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082656/image-185.png" alt="" class="wp-image-704163" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082656/image-185.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082656/image-185-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082656/image-185-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)</h3>
<ul>
<li>On Dec. 19, Citigroup analyst Alexander Hacking maintained Cleveland-Cliffs with a Neutral and lowered the price target from $12.5 to $11. The company's stock fell around 25% over the past month and<a href="https://www.benzinga.com/quote/CLF"> has a 52-week low</a> of $9.13.</li>
<li>RSI Value: 28</li>
<li>CLF Price Action: Shares of Cleveland-Cliffs gained 0.5% to close at $9.38 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">trend in CLF stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082719/image-186.png" alt="" class="wp-image-704164" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082719/image-186.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082719/image-186-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082719/image-186-768x708.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Quaker Chemical Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>)</h3>
<ul>
<li>On Nov. 18, Quaker Houghton board appointed Joseph Berquist as CEO and President, and a member of Board. The company's stock fell around 15% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/KWR">low of $137.65</a></li>
<li>RSI Value: 24</li>
<li>KWR Price Action: Shares of Quaker Chemical fell 1.7% to close at $138.61 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">KWR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="860" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082832/image-187.png" alt="" class="wp-image-704169" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082832/image-187.png 860w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082832/image-187-300x294.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23082832/image-187-768x753.png 768w" sizes="(max-width: 860px) 100vw, 860px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Top 3 Materials Stocks That May Rocket Higher In December

AILEW

Trading Halt: Halt status updated at 8:30:00 AM ET: Quotation Resumption: News and Resumption Times

Market-Moving Exclusives

EXCLUSIVE: La Rosa Holdings Tells Benzinga Co. To Offer Bitcoin And Cryptocurrency Payment Options To Its Real Estate Agents

Google-parent Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) has laid out its remedies proposal in the high-stakes <a href="https://www.benzinga.com/quote/GOOGL/news">search distribution case</a> with the Department of Justice (DOJ). 
JPMorgan analyst Doug Anmuth notes that Google's focus on non-exclusivity and increased flexibility aligns with its strategy to limit regulatory overreach. However, investors should also turn their attention to Google's operational strength, which could be a significant driver of long-term value.
<h2 class="wp-block-heading">Alphabet&#8217;s Remedies In DOJ Case</h2>
Google's proposal, filed on Dec. 20, sidesteps the harsher measures suggested by the DOJ, such as divestiture of Chrome or Android. Instead, the company's remedies focus on removing search exclusivity in browser and Android agreements and giving partners greater flexibility. 
This should allow partners like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and mobile carriers to preload multiple search engines. This shift could create opportunities for competitors, including Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), to vie for top spots.
Anmuth expects the judge's final decision in August 2025 to strike a balance between the DOJ and Google's proposals, likely considering user impacts. Still, the timing of remedy enforcement, appeals and potential injunctions adds uncertainty to financial implications.
Read Also: <a href="https://www.benzinga.com/24/12/42641018/google-faced-intense-scrutiny-post-chatgpt-leading-up-to-declaring-code-red-but-gemini-20-and-quantum-chip-gives-investors-renewed-confidence">Google Entered &#8216;Code Red&#8217; After ChatGPT Release, But Gemini 2.0 And Quantum Chip Give Investors &#8216;Renewed Confidence,&#8217; Says This Portfolio Manager</a>
<h2 class="wp-block-heading">&#8216;Tremendous Innovation In AI&#8217;, &#8216;New Buyback&#8217; Likely</h2>
While the legal battle unfolds, Alphabet's fundamentals remain robust. Anmuth emphasizes that Alphabet is demonstrating "tremendous innovation in AI," which continues to bolster healthy Search and overall ad revenue growth.
The company's ability to "durably re-engineer the cost base and expand margins" further strengthens its financial position. Moreover, Alphabet &#8220;will likely announce a new buyback authorization at 1Q earnings,&#8221; signaling confidence in future cash flows, says Anmuth.
<h2 class="wp-block-heading">Alphabet Among JPMorgan&#8217;s 2025 Top Picks</h2>
JPMorgan sees Alphabet as &#8220;one of our 2025 Top Picks&#8221;, alongside Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>). Anmuth projects a December 2025 price target of $232, supported by Alphabet's strong 30%+ operating income margin and double-digit percentage revenue growth. 
Beyond ads, Alphabet's non-ad businesses like Cloud and YouTube subscriptions hold significant growth potential. Meanwhile, ventures like Waymo and Verily offer optionality for future value.
<h2 class="wp-block-heading">The Road Ahead For Alphabet Stock Investors</h2>
Investor focus is shifting toward how a new administration could influence final remedies due in March 2025. A potential settlement or adjustments in Apple's search agreements could also sway outcomes. 
The court case may cast a shadow though Alphabet's core strengths are intact. Despite the regulatory noise, Alphabet stock remains a compelling play for investors seeking exposure to a leader in AI and digital transformation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42638753/quantum-computing-the-new-ai-a-look-at-the-rapidly-expanding-market-and-top-stocks-for-2025">Quantum Computing: The New AI? A Look at the Rapidly Expanding Market and Top Stocks For 2025</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

AAPL

AMZN

GOOG

GOOGL

MSFT

SPOT

Alphabet Defends DOJ Case, 'New Buyback' Likely From This '2025 Top Pick'

On December 20, 2024, Superior Group of Companies, Inc. (the "Company") entered into a 10b5-1 trading plan (the "Plan") for the purpose of repurchasing up to $2,580,000.00 in shares of the Company's outstanding common stock (the "Repurchase Limit") in accordance with the previously-announced share repurchase program authorized by the Company's Board of Directors on August 9, 2024. The Plan is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The Plan allows the Company to repurchase shares up to the Repurchase Limit commencing December 20, 2024 and ending on the earlier of the date on which the Repurchase Limit is reached, March 13, 2025, or other events specified in the Plan. Repurchases of common stock under the Plan will be administered through an independent broker and are subject to certain price, market, volume and timing constraints specified in the Plan.

Buybacks

Superior Group Announces Trading Plan For $2.58M Stock Buyback, Effective December 20 To March 13, 2025

TRAW

Traws Pharma shares are trading higher after they announced progress in the development of Tivoxavir Marboxi.

Our plants around the world are regularly inspected by health authorities to ensure compliance with the various markets we serve. Following an inspection by the U.S. FDA at our oral finished dose manufacturing facility in Indore, India earlier this year, the Agency has issued a Warning Letter, and an Import Alert related to this facility.
The Import Alert affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted. It makes exceptions, subject to certain conditions, for four products based on shortage concerns. There could be the potential for additional exceptions based on further discussions with the Agency.
Following the substance of FDA's original inspection observations, we immediately implemented a comprehensive remediation plan at the site. The necessary corrective and preventive actions are well underway, including but not limited to related personnel actions. Additionally, we have engaged independent third-party subject matter experts to support the remediation plan.
We have been in regular communication with FDA during this process and will continue to work to ensure that the Agency is satisfied with the steps we have taken to resolve all the points raised. Our response to the Warning Letter and Import Alert will be submitted within the required time periods.
At this time, we do not anticipate these actions impacting our current 2024 financial guidance ranges. We will incorporate&nbsp;potential future financial impact&nbsp;in our 2025 guidance ranges when we provide these in early 2025.
We take very seriously our continued and comprehensive oversight of our entire manufacturing network. Patient safety remains our primary and unwavering focus. We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve.

Global

Viatris Issues Statement Regarding Receipt Of Warning Letter And Import Alert For Indore, India Facility; The Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into The U.S. Until The Warning Letter Is Lifted

Citigroup analyst Gabriel Barra reinstates Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) with a Buy and announces $19 price target.

Initiation

CSAN

Citigroup Reinstates Buy on Cosan, Announces $19 Price Target

ALNY

GIVLAARI Gains Nationwide Reimbursement In Canada For Treating Acute Hepatic Porphyria

PLYA

Playa Hotels & Resorts shares are trading higher after Hyatt Hotels disclosed it executed an exclusivity agreement to potentially acquire the company.

AILE

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Elanco Animal Health ( ($ELAN) ) has provided an update. Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, enhancing its ...

Elanco Animal Health Strengthens Board with New Appointment

In a report released today, Glen Santangelo from Jefferies maintained a Buy rating on Elanco Animal Health (ELAN – Research Report), with a price t...

Jefferies Keeps Their Buy Rating on Elanco Animal Health (ELAN)

Elanco (ELAN) Animal Health acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Spe...

Elanco acquires contract manufacturing facility in Speke, UK

Elanco buys key U.K. manufacturing site for $25M

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Oppenheimer's top Buy and Sell ideas from each of the sectors

A class action lawsuit was filed against Elanco Animal Health Inc. ($ELAN) by Levi & Korsinsky on October 7, 2024. The plaintiffs (shareholders) al...

Class Action Lawsuit Against Elanco Animal Health Inc. (NYSE:ELAN)

Zoetis: Healing Paws, Growing Profits

Leerink analyst Daniel Clark initiated coverage of Elanco (ELAN) with a Market Perform rating and $14 price target The firm notes Elanco trades at ...

Elanco initiated with a Market Perform at Leerink

UBS initiated coverage of Elanco (ELAN) with a Buy rating and $18 price target The shares are down 19% year-to-date and 7% last week alone on Zenre...

Elanco initiated with a Buy at UBS

ANDE

BIIB

BNTX

CARS

CWEN

CYBR

HWKN

LMAT

LSCC

MRNA

MSGS

NAVI

PGNY

VRTX

Press Releases

ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit

Class Action Filed Against Elanco Animal Health Incorporated (ELAN) - December 6, 2024 Deadline to Join - Contact Levi & Korsinsky

Legal

ELAN CLASS ACTION DEADLINE IS TODAY: Elanco Investors are Alerted of December 6 Deadline in Securities Fraud Class Action – Contact BFA Law Now (NYSE:ELAN)

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health

ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco Animal Health Incorporated shares should contact the Shareholders Foundation

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines – ELAN

Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Elanco Animal Health

매도 수량

Elanco Animal Health (NYSE:ELAN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌